<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124432</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00220975</org_study_id>
    <secondary_id>R21DA044377</secondary_id>
    <nct_id>NCT04124432</nct_id>
  </id_info>
  <brief_title>Behavioral Pharmacology of Cannabis and Nicotine</brief_title>
  <official_title>Behavioral Pharmacology of Cannabis and Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the individual and interactive pharmacokinetic and pharmacodynamic&#xD;
      effects of smoked cannabis and nicotine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research&#xD;
      Unit (BPRU). All participants will be healthy adult volunteers who are regular&#xD;
      nicotine/tobacco users, and have prior experience with cannabis use. Participants will&#xD;
      complete seven outpatient experimental test sessions (completed in a randomized order), under&#xD;
      double-blind conditions in which participants will first self-administer smoked cannabis&#xD;
      (either active or placebo), followed by nicotine (via a tobacco cigarette or an e-cigarette);&#xD;
      there will also be one condition in which participants smoke active cannabis alone (without&#xD;
      subsequent nicotine use). Nicotine self-administration will occur in an ad libitum fashion&#xD;
      for 5 hours. Nicotine products will be the individual participant's preferred brand of&#xD;
      cigarettes or the commercial pod-style e-cigarette the JUUL (pods will contain either 3% or&#xD;
      5% nicotine pods). Active cannabis will contain 10 mg tetrahydrocannabinol (THC) while&#xD;
      placebo will contain 0 mg THC. During the ad libitum nicotine/tobacco-use period, various&#xD;
      puffing behaviors (e.g., puff volume, puff duration, puff number, inter-puff-interval) will&#xD;
      be measured using specialized equipment. Acute subjective effects of cannabis/nicotine,&#xD;
      cannabis/nicotine withdrawal symptoms, craving, vital signs, and cognitive/psychomotor&#xD;
      performance will also be assessed throughout the experimental sessions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All participants will complete all dose conditions (study arms) in a randomized order</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>placebo controlled, double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of nicotine (mL of smoke/vapor) inhaled</measure>
    <time_frame>5 hours</time_frame>
    <description>Amount of nicotine used (determined by total volume (mL) of cigarette smoke or JUUL vapor inhaled) after cannabis exposure in each session.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported Drug Effect as assessed by the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>5 hours</time_frame>
    <description>Peak rating (0-100) of Drug Effect on the DEQ, with 0 being no effect and 100 being maximum effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor performance as assessed by the Digit Symbol Substitution Task (DSST)</measure>
    <time_frame>5 hours</time_frame>
    <description>Computerized version of Digit Symbol Substitution Task will be administered to assess psychomotor performance. Total correct trials in 90-seconds. Minimum score of 0 but no maximum score (higher scores indicate better performance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory performance as assessed by the Paced Auditory Serial Addition Task (PASAT)</measure>
    <time_frame>5 hours</time_frame>
    <description>Computerized version of Paced Auditory Serial Addition Task will be administered to assess working memory performance. Total correct trials out of 90 recorded is primary outcome (higher scores indicate better performance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral task performance as assessed by the DRUID app</measure>
    <time_frame>5 hours</time_frame>
    <description>Behavioral task performance will be assessed with the DRUID app's Global impairment score(range 0-100), where lower scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobacco Craving as assessed by the Tobacco Craving Questionnaire</measure>
    <time_frame>5 hours</time_frame>
    <description>Peak rating (0-100) of &quot;Craving&quot; with 0 being no craving and 100 being maximum craving.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabis Craving as assessed by the Cannabis Craving Questionnaire</measure>
    <time_frame>5 hours</time_frame>
    <description>Peak rating (0-100) of &quot;Craving&quot; with 0 being no craving and 100 being maximum craving</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cannabis</condition>
  <condition>Nicotine</condition>
  <arm_group>
    <arm_group_label>Active cannabis without nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis containing 10mg THC + No nicotine/tobacco</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active cannabis with own brand cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active cannabis with low nicotine e-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active cannabis with high nicotine e-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo cannabis with own brand cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cannabis with low nicotine e-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cannabis with high nicotine e-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Cannabis will be smoked</description>
    <arm_group_label>Active cannabis with high nicotine e-cigarette</arm_group_label>
    <arm_group_label>Active cannabis with low nicotine e-cigarette</arm_group_label>
    <arm_group_label>Active cannabis with own brand cigarettes</arm_group_label>
    <arm_group_label>Active cannabis without nicotine</arm_group_label>
    <arm_group_label>Placebo cannabis with high nicotine e-cigarette</arm_group_label>
    <arm_group_label>Placebo cannabis with low nicotine e-cigarette</arm_group_label>
    <arm_group_label>placebo cannabis with own brand cigarettes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Nicotine will be smoked or vaporized</description>
    <arm_group_label>Active cannabis with high nicotine e-cigarette</arm_group_label>
    <arm_group_label>Active cannabis with low nicotine e-cigarette</arm_group_label>
    <arm_group_label>Active cannabis with own brand cigarettes</arm_group_label>
    <arm_group_label>Placebo cannabis with high nicotine e-cigarette</arm_group_label>
    <arm_group_label>Placebo cannabis with low nicotine e-cigarette</arm_group_label>
    <arm_group_label>placebo cannabis with own brand cigarettes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have provided written informed consent&#xD;
&#xD;
          -  Be between the ages of 18 and 55&#xD;
&#xD;
          -  Be in good general health based on a physical examination, medical history, vital&#xD;
             signs, and screening urine and blood tests&#xD;
&#xD;
          -  Test negative for drugs of abuse aside from cannabis (via urine sample) and alcohol&#xD;
             (via breath sample) at the screening visit and upon arrival for each experimental&#xD;
             session.&#xD;
&#xD;
          -  Not be pregnant or nursing (if female). All females must have a negative serum&#xD;
             pregnancy test at the screening visit and a negative urine pregnancy test at clinic&#xD;
             admission.&#xD;
&#xD;
          -  Have a body mass index (BMI) in the range of 18 to 36 kg/m2&#xD;
&#xD;
          -  Blood pressure at screening visit does not exceed a systolic blood pressure (SBP) of&#xD;
             150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg&#xD;
&#xD;
          -  Have not donated blood in the prior 30 days.&#xD;
&#xD;
          -  Report prior experience inhaling cannabis.&#xD;
&#xD;
          -  Report using cannabis at least 5 times in the past year.&#xD;
&#xD;
          -  Smoke ≥5 tobacco cigarettes per day on average in the past month.&#xD;
&#xD;
          -  Use an e-cigarette at least 15 of the past 30 days.&#xD;
&#xD;
          -  Have a breath carbon monoxide (CO) of &gt;8ppm or urine cotinine &gt;200ng/mL to confirm&#xD;
             current nicotine use status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-medical use of psychoactive drugs (aside from cannabis) other than, nicotine,&#xD;
             alcohol, or caffeine in the month prior to the Screening Visit;&#xD;
&#xD;
          -  History of or current evidence of significant medical or psychiatric illness which, in&#xD;
             the opinion of the investigator or sponsor, will interfere with the study results or&#xD;
             the safety of the subject.&#xD;
&#xD;
          -  Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s),&#xD;
             or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the&#xD;
             investigator or sponsor, will interfere with the study results or the safety of the&#xD;
             subject.&#xD;
&#xD;
          -  Use of a prescription medication (with the exception of birth control prescriptions)&#xD;
             within 14 days of experimental sessions; which, in the opinion of the investigator or&#xD;
             sponsor, will interfere with the study results or the safety of the subject.&#xD;
&#xD;
          -  History of clinically significant cardiac arrhythmias or vasospastic disease (e.g.,&#xD;
             Prinzmetal's angina).&#xD;
&#xD;
          -  Enrolled in another clinical trial or have received any drug as part of a research&#xD;
             study within 30 days prior to dosing.&#xD;
&#xD;
          -  Epilepsy or a history of seizures.&#xD;
&#xD;
          -  Individuals who have a recent history of traumatic brain injury diagnosed by CT/MRI&#xD;
             and have current sequela from prior brain injury, as determined by the study physician&#xD;
&#xD;
          -  Individuals with anemia.&#xD;
&#xD;
          -  Prior history of allergic or serious adverse reaction to either cannabis or&#xD;
             tobacco/nicotine.&#xD;
&#xD;
          -  Average use of cannabis more than 2 times per week in the prior 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cecilia Bergeria</last_name>
    <phone>410-550-1979</phone>
    <email>cberge21@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan Vandrey</last_name>
    <phone>410-550-4036</phone>
    <email>rvandrey@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Bergeria</last_name>
      <phone>410-550-1979</phone>
      <email>cberge21@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

